US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

NEWTON, MA, USA I 12, 2025 I Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.

New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...

The positive predictive value (PPV) of myositis antibodies for diagnosing myositis and its related conditions differs by individual antibody type. Greater diagnostic accuracy is associated with ...

Now, the veteran guitarist and singer-songwriter is making medical history as he bravely battles inclusion body myositis. IBM ...